Chemotherapy: New Uses for Old Drugs

Veterinary Clinics of North America - Small Animal Practice

Volumn 37, Issue 6, 2007, Pages 1079-1090

  Mutsaers, Anthony J ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; ABT 526; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; DOXYCYCLINE; ETOPOSIDE; METHOTREXATE; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; PIROXICAM; PLACEBO; PREDNISONE; THALIDOMIDE; THROMBOSPONDIN 1; UFT; UNCLASSIFIED DRUG; VASCULOTROPIN; VINCRISTINE;

ADJUVANT THERAPY; ANGIOSARCOMA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CARCINOGENESIS; CYTOTOXICITY; DOG DISEASE; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG POTENTIATION; DRUG TARGETING; ENDOTHELIUM CELL; LONG TERM CARE; LOW DRUG DOSE; LYMPHOMA; MAINTENANCE THERAPY; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM TOLERATED DOSE; NONHUMAN; OPTIMAL DRUG DOSE; PROSTATE CARCINOMA; RADIATION DOSE FRACTIONATION; RADIOSENSITIZATION; REVIEW; STEM CELL; TUMOR CELL; VETERINARY MEDICINE;

ANIMALS; ANTINEOPLASTIC AGENTS; NEOPLASMS;

EID: 35348842679     PISSN: 01955616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cvsm.2007.07.002     Document Type: Review

References (56)

1. Kosarek C.E., Kisseberth W.C., Gallant S.L., et al. Clinical evaluation of gemcitabine in dogs with spontaneously occurring malignancies. J Vet Intern Med 19 1 (2005) 81-86
2. Rassnick K.M., Frimberger A.E., Wood C.A., et al. Evaluation of ifosfamide for treatment of various canine neoplasms. J Vet Intern Med 14 3 (2000) 271-276
3. Poirier V.J., Burgess K.E., Adams W.M., et al. Toxicity, dosage and efficacy of vinorelbine (Navelbine) in dogs with spontaneous neoplasia. J Vet Intern Med 18 4 (2004) 536-539
4. Moore A.S., Kirk C., and Cardona A. Intracavitary cisplatin chemotherapy experience with six dogs. J Vet Intern Med 5 4 (1991) 227-231
5. Jones P.D., de Lormier L.P., Kitchell B.E., et al. Gemcitabine as a radiosensitizer for nonresectable feline oral squamous cell carcinoma. J Am Anim Hosp Assoc 39 5 (2003) 463-467
6. Hanahan D.J., Bergers G., and Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105 (2000) 1045-1047
7. Browder T., Butterfield C.E., Kraling B.M., et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60 (2000) 1878-1886
8. Klement G., Baruchel S., Rak J., et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105 (2000) R15-R24
9. Skipper H.E., Schabel F.M., and Mellet L.B. Implications of biochemical, cytokinetic, pharmacologic and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother Rep 54 (1970) 431-450
10. Kamen B.A., Rubin E., Glatstein E., et al. High-time chemotherapy or high time for low dose. J Clin Oncol 18 (2000) 2935-2937
11. Kamen B.A. Metronomic therapy: it makes sense and is patient friendly. J Pediatr Hematol Oncol 27 (2005) 571-572
12. Kerbel R.S., and Kamen B.A. Antiangiogenic basis of low-dose metronomic chemotherapy. Nat Rev Cancer 4 (2004) 423-436
13. Miller K.D., Sweeney C.J., and Sledge G.W. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 19 (2001) 1195-1206
14. Emmenegger U., Man S., Shaked Y., et al. A comparative analysis of low dose metronomic cyclophosphamide reveals absent or low grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res 64 (2004) 3994-4000
15. Bocci G., Nicolaou K.C., and Kerbel R. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 62 (2002) 6938-6943
16. Wang J., Lou R., Lesniewski R., et al. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs 14 (2003) 13-19
17. Vacca A., Iurlaro M., Ribatti D., et al. Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 94 (1999) 4143-4155
18. Asahara T., Murahara T., Sullivan A., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275 5302 (1997) 964-967
19. Bertolini F., Paul S., Mancuso P., et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63 (2003) 4342-4346
20. Man S., Bocci G., Francia G., et al. Antitumor and anti-angiogenic effects in mice of low dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 62 (2002) 2731-2735
21. Shaked Y., Emmenegger U., Man S., et al. The optimal biological dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 106 (2005) 3058-3061
22. Shaked Y., Bertolini F., Man S., et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cells 7 (2005) 101-111
23. Schneider M., Tjwa M., and Carmeliet P. A surrogate marker to monitor angiogenesis at last. Cancer Cells 7 (2005) 3-4
24. Rusk A., McKeegan E., Haviv F., et al. Preclinical evaluation of anti-angiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers. Clin Cancer Res 12 24 (2006) 7444-7455
25. Kerbel R.S. Therapeutic implications of intrinsic or induced angiogenic growth factor redundancy in tumors revealed. Cancer Cells 8 (2005) 269-271
26. Rak J., Yu J.L., Kerbel R.S., et al. What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors?. Cancer Res 62 7 (2002) 1931-1934
27. Bocci G., Francia G., Man S., et al. Thombospondin-1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci U S A 100 (2003) 12917-12922
28. Hamano Y., Sugimoto H., Soubasakos M.A., et al. Thombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res 64 (2004) 1570-1574
29. Yap R., Veliceasa D., Emmenegger U., et al. Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy. Clin Cancer Res 11 (2005) 6678-6685
30. Kieran M.W., Turner C.D., Rubin J.B., et al. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol 27 11 (2005) 573-581
31. Damber J.E., Vallbo C., Albertsson P., et al. The anti-tumor effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin. Cancer Chemother Pharmacol 58 (2006) 354-360
32. Rusk A., Cozzi E., Stebbins M., et al. Cooperative activity of cytotoxic chemotherapy with antiangiogenic thrombospondin-1 peptides, ABT-526 in pet dogs with relapsed lymphoma. Clin Cancer Res 12 24 (2006) 7456-7464
33. Tran J., Master Z., Yu J.L., et al. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci U S A 99 (2002) 4349-4354
34. Ogawa Y., Ishikawa T., Chung S.H., et al. Oral UFT and cyclophosphamide combination chemotherapy for metastatic breast cancer. Anticancer Res 23 (2003) 3453-3457
35. Nio Y., Iguchi C., Kodama H., et al. Cyclophosphamide augments the anti-tumor efficacy of uracil and tegafur by inhibiting dihydropyrimidine dehydrogenase. Oncol Rep 17 (2007) 153-159
36. Munoz R., Man S., Shaked Y., et al. Highly efficacious non-toxic treatment for advanced metastatic breast cancer using combination UFT-cyclophosphamide metronomic chemotherapy. Cancer Res 66 (2006) 3386-3391
37. Colleoni M., Rocca A., Sandri M.T., et al. Low dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 13 (2002) 73-80
38. Orlando L., Cardillo A., Rocca A., et al. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. Anticancer Drugs 17 (2006) 961-967
39. Buckstein R., Crump M., Shaked Y., et al. High dose celecoxib and metronomic "low dose" cyclophosphamide is effective and safe therapy in patients with relapsed and refractory aggressive histology NHL. Clin Cancer Res 12 (2006) 5190-5198
40. Vogt T., Hafner C., Bross K., et al. Antiangiogenic therapy with pioglitazone, rofecoxib, and metronomic trofosphamide in patients with advanced malignant vascular tumors. Cancer 98 (2003) 2251-2256
41. Kopp H.G., Kanz L., and Hartmann J.T. Complete remission of relapsing high-grade angiosarcoma with single-agent metronomic trophosphamide. Anticancer Drugs 17 (2006) 997-998
42. Reichle A., Bross K., Vogt T., et al. Pioglitazone and rofecoxib combined with angiostatically scheduled trofosphamide in the treatment of far-advanced melanoma and soft tissue sarcoma. Cancer 101 (2004) 2247-2256
43. Lord R., Nair S., Schache A., et al. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study. J Urol 177 (2007) 2136-2140
44. Glode L.M., Crighton F., Barqawi A., et al. Metronomic therapy with cyclophosphamide and dexamethasone for prostate cancer. Cancer 98 (2003) 1643-1648
45. Kong D.S., Lee J.I., Kim W.S., et al. A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. Oncol Rep 16 (2006) 1117-1121
46. Correale P., Cerretani D., Remondo C., et al. A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients. Oncol Rep 16 (2006) 133-140
47. Krzyzanowska M.K., Tannock I.F., Lockwood G., et al. A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma. Cancer Chemother Pharmacol 60 (2007) 135-141
48. Mutsaers AJ, Mohammed SI, DeNicola DB, et al. "Metronomic" chemotherapy in veterinary oncology, a pilot study [abstract]. In: Proceedings of the 21st veterinary cancer society conference. Baton Rouge (LA), 2001. p. 41.
49. Lana S, U'Ren L, Plaza S, et al. Comparison of continuous low-dose oral chemotherapy with conventional doxorubicin chemotherapy for adjuvant therapy of hemangiosarcoma in dogs [abstract]. In: Proceedings of the 26th veterinary cancer society conference. Pine Mountain (GA), 2006. p. 84.
50. Flory AB, Rassnick KM, Balkman CE, et al. Bioavailability and pharmacokinetics of an oral preparation of etoposide in tumor-bearing dogs [abstract]. In: Proceedings of the 26th veterinary cancer society conference. Pine Mountain (GA), 2006. p. 29.
51. Garrett L.D., Thamm D.H., Chun R., et al. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 16 6 (2002) 704-709
52. Ogilvie G.K., Vail D.M., Klein M.K., et al. Weekly administration of low-dose doxorubicin for treatment of malignant lymphoma in dogs. J Am Vet Med Assoc 198 10 (1991) 1762-1764
53. Hahn K.A., Rohrbach B.W., Legendre A.M., et al. Hematologic changes associated with weekly low-dose cisplatin administration in dogs. Vet Clin Pathol 26 1 (1997) 29-31
54. Shaked Y., Emmenegger U., Francia G., et al. Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res 65 (2005) 7045-7051
55. Kato H., Ichinose Y., Ohta M., et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350 (2004) 1713-1721
56. Mancuso P., Colleoni M., Calleri A., et al. Circulating endothelial cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 108 (2006) 452-459